• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations

Posted on: Thursday, 18 June 2009, 13:20 CDT

ARLINGTON, Va., June 18 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations. Designed to provide guidance for life science suppliers selling products that support epigenetic research involving chromosome immunoprecipitation (chIP), this report will help suppliers optimize product offerings and strengthen market position. For this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 56-question survey to scientists worldwide about their current--and planned--areas of study in epigenetics research, usage of related products and preferred suppliers.

The report is scheduled to release in mid-July, and is available at pre-release pricing until July 15, 2009.

Advances enabling faster and cheaper mapping of epigenetic modifications have accelerated discoveries in the field. Since 2007, the National Institutes of Health has supported these efforts with the creation and funding of the Epigenomics Roadmap Initiative, which promotes the discovery of epigenetic markers and the development of new epigenetics-based tools. Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations reviews progress in both of these areas and highlights opportunities for suppliers interested in designing and manufacturing new technologies to support epigenetics researchers. In this study, scientists elaborate on processes and techniques they use to do epigenetics research, problems with protocols and antibodies, changes expected in the time/effort devoted to epigenetics research over the next couple of years and the estimated change in spending on chIP consumables through 2011.

Scientists also provide opinions about suppliers of chIP and non-chIP grade antibodies, and indicate how these products are used, satisfaction with suppliers and desired improvements with each. The following suppliers were provided as choices in the survey:

Abcam (LSE: ABC.L)

Abnova

Active Motif

Affinity Bioreagents (Thermo Fisher Scientific (NYSE: TMO))

Alexis Biochemicals (Enzo Life Sciences) (NYSE: ENZ)

Aviva Systems Biology

BD Biosciences Immunocytometry Systems

BD Biosciences Pharmingen (NYSE: BDX)

Beckman Coulter (NYSE: BEC)

Bethyl Laboratories

BioChemika (Sigma-Aldrich) (NasdaqGS: SIAL)

Biogenesis (MorphoSys)

BioGenex

BIOMOL (Enzo Life Sciences)

BioSource (Life Technologies) (NasdaqGS: LIFE)

Calbiochem (EMD) (NYSE: EMD)

Caltag (life Technologies)

Cell Signaling Technology

Chemicon International (Millipore) (NYSE: MIL)

Covance (NYSE: CVD)

Dako

Diagenode

Dynal Biotech (Life Technologies)

eBioscience

Endogen (Thermo Fisher Scientific)

GE Healthcare (Amersham) (NYSE: GE)

Imgenex

Invitrogen (Life Technologies) (Nasdaq: LIFE)

Jackson ImmunoResearch Laboratories

KPL

LabVision Corporation (Thermo Fisher Scientific)

Miltenyi Biotech

Millipore (NYSE: MIL)

Molecular Probes (Life Technologies)

NeoMarkers (Thermo Fisher Scientific)

Novus Biologicals

Pierce (Thermo Fisher Scientific)

Promega

Quantum Dot (Life Technologies (Invitrogen))

R&D Systems (division of TECHNE Corp., Nasdaq: TECH)

Roche Applied Science

Rockland Immunochemicals

SABiosciences

Santa Cruz Biotechnology

Serotec (MorphoSys)

Sigma-Aldrich (Nasdaq: SIAL)

Upstate (Millipore)

Vector Laboratories

Zymed (Life Technologies (Invitrogen))

"While the majority of the survey respondents are involved in gene regulation studies, changes to the epigenetic state play a central role in many diseases. Cancer is one of the best-studied examples, but many other pathologies, including diabetes, neurological disorders, and aging may have epigenetic contributions," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo has been the senior analyst on over 80 syndicated market research reports, and presented findings from Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations at the 2009 Consumer Genetics Show at the Hynes Convention Center in Boston, MA on June 9.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/203/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 43,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information contact: Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) m.follin@gene2drug.com http://www.gene2drug.com/

SOURCE BioInformatics, LLC

Source: PR Newswire

More News in this Category